首页> 美国卫生研究院文献>Journal of Movement Disorders >Neuroleptic Malignant Syndrome in a Patient with Corticobasal Degeneration
【2h】

Neuroleptic Malignant Syndrome in a Patient with Corticobasal Degeneration

机译:皮质基底变性患者的抗精神病药恶性综合征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Parkinson’s disease is a principal underlying disease of neuroleptic malignant syndrome (NMS) occurring in parkinsonian disorders, but NMS may occur in patients with progressive supranuclear palsy and multiple system atrophy. We report first patient with corticobasal degeneration (CBD) who developed NMS after abrupt reduction of antiparkinsonian medication and concurrent infection. It should be kept in mind that the prevention of infectious illness, which is common complication in parkinson-plus syndrome, is important, and dose reduction or withdrawal of anti-parkinsonian medications should be carefully performed even in the patients with CBD who are expected to be unresponsive to levodopa treatment.
机译:帕金森氏病是发生在帕金森氏病中的主要精神疾病恶性综合症(NMS),但NMS可能发生在进行性核上性麻痹和多系统萎缩的患者中。我们报道了首例皮质类固醇变性(CBD)患者,其在突然减少抗帕金森病药物和并发感染后发展为NMS。应当牢记,预防帕金森氏综合症常见的传染病很重要,即使在预期会发生CBD的CBD患者中,也应谨慎进行减量或停药抗帕金森氏病药物对左旋多巴治疗无反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号